Lynn spoke with Robert Thomas, MD, MMSC on 'The Science of Sleep.' Robert explains how modernization has produced a cultural disrespect for sleep, and how sleep may help prevent obesity, cardiovascular disease and neurological disorders.
Perhaps sleep, just like taking a statin, can be as much a preventive measure as it is a necessity when we show symptoms of disease. Podcast in 4min30sec.
Last week we had some old friends and some new friends come together here at MGH to discuss the future of Life Sciences and innovative opportunities for business development and venture capital investment. You'll know Juan Enriquez from his ground breaking book As The Future Catches You. Luis Barros comes to us from the Massachusetts Life Sciences Center, where they focus on creating jobs in the Commonwealth by developing Boston as the center for biotechnology around the world. David Constantine is a new CIMIT face coming from the initiative, MassChallenge, a Collaboration and Competition model just getting started. Finally, John Abele, served as the continual driving force behind a need for better collaboration in medicine.
Moderator:
Richard Anders, Managing Director, Rubin/Anders Scientific, Inc.
Innovation has charged the world’s
biotech and medical device industries, academic medical centers, universities
and global health organizations. In the context of the current United
States debate over HealthCare Reform, Enriquez and Barros will
discuss the impact and outlook for life science innovation.
Why Life Sciences will be
the Dominant Language and Economic Driver of this Century
As we live through an almost unprecedented economic crisis, we are also
living through an extraordinary scientific age. On the one hand, we
are witnessing unprecedented wealth destruction. On the other hand there
are, especially in Boston, extraordinary opportunities to create the
next great industries and power the global economy.
The life science revolution is
already having extraordinary political, ethical, economic, and financial
impacts. You can begin to see this in both the pattern of mergers and
acquisitions as well as new investments.
Life science applications are
transforming how pharma, biotech, food, feed, fiber, insurance, chemical,
insurance, and energy companies do business.
Luis Barros is the Vice President for Investments and Industry Development
for the Massachusetts Life Sciences Center, the quasi-public agency
charged with implementing the state's ten-year, $1 billion Life Sciences
Initiative. His presentation will discuss the Center's investment strategy,
the investments made thus far, and the return on investment to date.
19 NOVEMBER 2009, BOSTON - Zen Chu (Accelerated
Medical Ventures and CIMIT's Innovation Grand Rounds) recently
testified at the FDA's public hearings on Social Media and Internet (#FDASM).
The FDA is grappling with a number of questions centered around
regulation and accountability for Healthcare and the use of Social
Media, with implications for direct-to-consumer advertising, patient
safety, adverse event reporting, disease management, and new technology
innovation.
The
FDA thought it wise to bring together qualified experts from a wide
range of areas to give testimony. Streaming video available for the next 20 days:http://www.fdasm.com/
I thought Zen had an interesting
testimony, perspective and has shared it with us.
Zen Chu: My purpose was to lend an innovation and new ventures perspective to the FDA panel:
FDA should lend clarity to regulations and exercise restraint to enable new technologies and services to engage patients
FDA needs to distinguish between ads and messages delivered to benefit wellness, compliance, adherence
FDA must hire more expertise in new media and technology to understand and provide more timely guidelines
A
New Media & Technology Advisory Board, comprise of both industry,
academia and patient advocates should be created to advise FDA
18 NOVEMBER 2009, BOSTON - Nice old piece on Socialnomics, which has been seen a lot by now, but with the FDA Public Hearings on Social Media (#FDASM) I think it is appropriate to bring it back and refresh us. The Social Media Revolution...
10 NOVEMBER 2009 - BOSTON It is with a heavy heart that CIMIT says goodbye to our friend and colleague Dr. Don Baim. Don passed away last Friday, 6 November 2009, following complications of surgery to treat adrenal cancer.
We will remember Don as a former CIMIT Site Miner (one of many roles here) and as someone who continually pushed medicine forward -- be it from Harvard Medical to Boston Scientific. He was a Forum speaker, a panelist multiple times and from time to time we found him in the audience of Forums focused on Venture Capitalism in Medicine.
This morning John Parrish called a moment of silence for Don here at CIMIT and we remembered how much he gave to medicine and the better outcomes he helped produce.
Don was a friend to all of us here and his loss is a tremendous one.
A clinical focus group on epilepsy will convene on October 27th &28th in Boston
BOSTON, 19 October 2009 - Millions of Americans and their families live every day with the immensechallenges of epilepsy. Seizures that strike unpredictably at any momentand cause injury or even death; treatment side effects that continuallyimpair thinking, emotions and coordination; related medical andpsychological conditions; limitations in learning, driving andemployment; and social stigma are just a few of these many challenges.
We need new treatments. We need new diagnostic tests to be able tochoose the best treatments. We need new approaches to thinking abouttreatments. And we need people living with epilepsy to keep us focused and on track.
That's why physicians, engineers and others are convening at the
upcoming CIMIT Innovation Congress to hear from people directly impacted
by epilepsy.
In addition, a panel discussion will explore ways to accelerate the movement of new technologies from academiclaboratories to patient care. I know how difficult it can be to introducenew technologies for epilepsy therapy, yet the same challenge holds truefor all diseases -- cancer, heart disease, and more. Patient advocatesare critical voices in these endeavors.
Recent Comments